Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Comment by lscfaon Feb 28, 2017 8:14pm
193 Views
Post# 25909204

RE:RE:ebitda emphasis is sort changing the co.

RE:RE:ebitda emphasis is sort changing the co.The example used trailing no.s for comparision purposes only....we know that Q4 ebitda is to be 25% higher than Q1 editda, so

1.25 x $10.85 = $13.56 for a $54.25 million annualized run rate

EV / ebitda multiple of 7 => $380 mil EV

less debt of $136.5 => $243.25 mkt cap

117 mil shs. => $2.08

<< Previous
Bullboard Posts
Next >>